Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States

Jingbo Yu, Kristin J. Moore, Nicole M Engel-Nitz, Mary DuCharme, John Galvin, Valkal Bhatt, Catherine J. Lee

Blood (2024) 144 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2024-200781

Published: 2024

Journal Articles

Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib

Naveen Pemmaraju, Jingbo Yu, Anupama Vasudevan, Husain Qureshi, Evan M. Braunstein, Aleksander L. Chojecki

Blood (2024) 144 (Supplement 1): 3813.

https://doi.org/10.1182/blood-2024-205193

Published: 2024

Journal Articles

Cost Comparison of Ruxolitinib and Momelotinib in Patients with Myelofibrosis and Anemia

Aaron T. Gerds, Jingbo Yu, Charles Tao, Rashad Carlton, Evan M. Braunstein, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 6655.

https://doi.org/10.1182/blood-2024-193686

Published: 2024

Journal Articles

Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States

Jingbo Yu, Kristin J. Moore, Nicole M. Engel-Nitz, Mary DuCharme, Britnie Thomas, John Galvin, Valkal Bhatt

Blood (2024) 144 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2024-208047

Published: 2024

Journal Articles

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Aaron T. Gerds, Ruben Mesa, John M. Burke, Michael R. Grunwald, Brady L. Stein, Peg Squier, Jingbo Yu, J. E. Hamer-Maansson, Stephen T. Oh

Blood (2024) 143 (16): 1646–1655.

https://doi.org/10.1182/blood.2023020232

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices

Srdan Verstovsek, Jingbo Yu, Emily Bland, Tammy Schuler, Thomas Cordaro, Evan Braunstein

Blood (2022) 140 (Supplement 1): 8131–8132.

https://doi.org/10.1182/blood-2022-169426

Published: 2022

Journal Articles

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Roger M. Lyons, Kathleen M. Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu

Blood (2022) 140 (Supplement 1): 13310–13311.

https://doi.org/10.1182/blood-2022-163416

Published: 2022

Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa

Blood (2022) 140 (Supplement 1): 6810–6812.

https://doi.org/10.1182/blood-2022-158144

Published: 2022

Journal Articles

Direct and Indirect Costs of Patients with Myeloproliferative Neoplasm Diseases

Jingbo Yu, Michelle Jerry, James Nelson, Taylor Marlin, Evan Braunstein, Nicole Princic

Blood (2022) 140 (Supplement 1): 5268–5269.

https://doi.org/10.1182/blood-2022-166758

Published: 2022

Journal Articles

Disability Associated with Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Paul Williams, Giulio Flore, John Galvin, James Turnbull, Jingbo Yu

Blood (2021) 138 (Supplement 1): 4060.

https://doi.org/10.1182/blood-2021-153201

Published: 2021

Journal Articles

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Aaron T. Gerds, Ruben A. Mesa, John M. Burke, Michael R. Grunwald, Brady Lee Stein, Robyn Scherber, Jingbo Yu, J.E. Hamer-Maansson, Stephen Oh

Blood (2021) 138 (Supplement 1): 239.

https://doi.org/10.1182/blood-2021-148509

Published: 2021

Journal Articles

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-141370

Published: 2020

Journal Articles

Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, MD PhD, Robyn M. Scherber, MD, Shivani Pandya, MS, Christopher Dieyi, MPH, Chien-Cheng Chen, MS, Shreekant Parasuraman, BPharm, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141090

Published: 2020

Journal Articles

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Brady L. Stein, MD MHSc, Kamal Patel, MD, Robyn M. Scherber, MD, Jingbo Yu, MD PhD, Dilan Paranagama, PhD, Carole B. Miller, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137144

Published: 2020

Journal Articles

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Jingbo Yu, MD PhD, Shreekant Parasuraman, BPharm, PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-141333

Published: 2020

Journal Articles

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Srdan Verstovsek, MD PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Shambhavi Kumar, MS, Ann Xi, PharmD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140820

Published: 2020

Journal Articles

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Jingbo Yu, PhD, Becky Hanna, Dilan Paranagama, PhD, Jackson Tang, Ahmad Naim, MD, John P Galvin, MDMS,MPH

Blood (2019) 134 (Supplement_1): 1994.

https://doi.org/10.1182/blood-2019-127492

Published: 2019

Journal Articles

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Paranagama, PhD, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 5385.

https://doi.org/10.1182/blood-2019-123833

Published: 2019

Journal Articles

Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey

Simon Condliffe, PhD MS, Jingbo Yu, PhD, Dilan Chamikara Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD

Blood (2018) 132 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2018-99-115345

Published: 2018

Journal Articles

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Chamikara Paranagama, PhD, Jill Kaufman, Jessica Chung, PhD MPH, Michael R. Grunwald, MD, Philomena Colucci, DO, MS, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2018-99-115294

Published: 2018

NARROW

Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States

Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib

Cost Comparison of Ruxolitinib and Momelotinib in Patients with Myelofibrosis and Anemia

Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil in the United States

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Direct and Indirect Costs of Patients with Myeloproliferative Neoplasm Diseases

Disability Associated with Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only